Mechanistic studies also indicate that CD103 is induced after specific activation of T cells against their cognate target [30–32], and the number of CD103+ cells increases significantly during successful immune checkpoint inhibitor treatment in lung and bladder cancer [24], melanoma [21], and non-small cell lung cancer patients [33]. This evidence concerns the gene ITGAE and urinary bladder cancer.